GlassScriptPhysician profile
Brian K Flanagan
NPI 1962489930
$4,625.45
in general payments reported to CMS, 2019-2025
48 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $458 · 2021: $396 · 2022: $523 · 2023: $529 · 2024: $562 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $594.58 | 2019-2025 | Xtampza |
| Abbvie INC. | $508.63 | 2021-2025 | |
| Boston Scientific Corporation | $506.70 | 2019-2025 | Intracept, Artisan |
| Nevro Corp. | $409.94 | 2019-2022 | |
| Pfizer INC. | $212.03 | 2019-2025 | |
| Abbott Laboratories | $188.68 | 2019-2025 | Proclaim, Eterna |
| Si-Bone, INC. | $183.53 | 2019-2023 | |
| Medtronic, INC. | $182.69 | 2022 | |
| Allergan, INC. | $171.06 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.93 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $120.21 | 2019-2022 | |
| Amgen INC. | $79.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $73.04 | 2019 | |
| Valinor Pharma, LLC | $72.52 | 2023-2025 | Movantik |
| Nalu Medical, INC. | $67.14 | 2021-2025 | Nalu Neurostimulation System |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.